Newsroom

VectorBuilder has announced its plan to invest $30 million to build an ‘AAV Superbank’ for the research and drug discovery community. Read More ››

VectorBuilder Inc. – a global leader in gene delivery solutions – has announced the construction of a new R&D and manufacturing center in Guangzhou, China. The ‘Gene Delivery Research and Manufacturing Campus’ will significantly expand VectorBuilder’s R&D capabilities and its production capacity for both research-use and cGMP-grade gene delivery vectors, allowing the company to continue supporting groundbreaking research worldwide. Read More ››

As we rapidly expand from a pure research focus into the clinical market, this partnership will help the company to create optimized, efficient and automated GMP manufacturing platforms. Read More ››

VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have signed a strategic partnership that will establish the world’s first primate gene therapy R&D center. Read More ››

“We are extremely pleased to be partnering with Univercells Technologies to co-develop optimized, scalable and customizable solutions for fast and affordable production of viral vectors. This partnership is an important step in VectorBuilder’s ambition to become a global leader in high performance, commercial-scale biomanufacturing,” said Dr Jason Ye, Vice President of Biomanufacturing at VectorBuilder. Read More ››

Dr. Miho Matakatsu, Managing Director of VectorBuilder Japan, was recently interviewed by JETRO (Japan External Trade Organization) to share VectorBuilder’s success stories in Japan. Read More ››